Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study
Journal of Cancer Research and Clinical Oncology · 2024
DOI: 10.1007/s00432-024-05618-4 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Tadahiro Kuribayashi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, O…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Okayama University.
Abstract (Originalsprache)
Purpose
Immune checkpoint inhibitors (ICIs) are ineffective against epidermal growth factor receptor ( EGFR )-mutant non-small cell lung cancer (NSCLC). This study aimed to investigate the clinical characteristics of patients who were treated or not treated with ICIs, and of those who benefit from immunotherapy in EGFR -mutant NSCLC.
Methods
We analyzed patients with unresectable stage III/IV or recurrent NSCLC harboring EGFR mutations using a prospective umbrella-type lung cancer registry (CS-Lung-003).
Results
A total of 303 patients who met the eligibility criteria were analyzed. The median age was 69 years; 116 patients were male, 289 had adenocarcinoma, 273 had major mutations, and 67 were treated with ICIs. The duration of EGFR-TKI treatment was longer in the Non-ICI group than in the ICI group (17.1 vs. 12.7 months, p < 0.001). Patients who received ICIs for more than 6 months were categorized into the durable clinical benefit (DCB) group (24 patients), and those who received ICIs for less than 6 months into the Non-DCB group (43 patients). The overall survival in the DCB group exhibited longer than the Non-DCB group (69.3 vs. 47.1 months), and an equivalent compared to that in the Non-ICI group (69.3 vs. 68.9 months). Multivariate analysis for time to next treatment (TTNT) of ICIs showed that a poor PS was associated with a shorter TTNT [hazard ratio (HR) 3.309; p < 0.001]. Patients who were treated with ICIs and chemotherapy combination were associated with a longer TTNT (HR 0.389; p = 0.003). In addition, minor EGFR mutation was associated with a long TTNT (HR 0.450; p = 0.046).
Conclusion
ICIs were administered to only 22% of patients with EGFR -mutated lung cancer, and they had shorter TTNT of EGFR-TKI compared to other patients. ICI treatment should be avoided in EGFR mutated lung cancer with poor PS but can be considered for lung cancer with EGFR minor mutations. Pathological biomarker to predict long-term responders to ICI are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
- Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan. kohashi@cc.okayama-u.ac.jp.
- Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
- Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Faculty of Medicine, Shimane University, Izumo, Japan.
- Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
- Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.
Förderung
- Okayama University
Zitieren
APA
Kuribayashi, T., Ohashi, K., Nishii, K., Ninomiya, K., Tsubata, Y., Ishikawa, N., Kodani, M., Kanaji, N., Yamasaki, M., Fujitaka, K., Kuyama, S., Takigawa, N., Fujimoto, N., Kubota, T., Inoue, M., Fujiwara, K., Harita, S., Takata, I., Takada, K., …, & Hotta, K. (2024). Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05618-4
Vancouver
Kuribayashi T, Ohashi K, Nishii K, Ninomiya K, Tsubata Y, Ishikawa N, et al. Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05618-4
BibTeX
@article{Kuribayashi2024,
author = {Kuribayashi, Tadahiro and Ohashi, Kadoaki and Nishii, Kazuya and Ninomiya, Kiichiro and Tsubata, Yukari and Ishikawa, Nobuhisa and Kodani, Masahiro and Kanaji, Nobuhiro and Yamasaki, Masahiro and Fujitaka, Kazunori and Kuyama, Shoichi and Takigawa, Nagio and Fujimoto, Nobukazu and Kubota, Tetsuya and Inoue, Masaaki and Fujiwara, Keiichi and Harita, Shingo and Takata, Ichiro and Takada, Kenji and Okawa, Sachi and Kiura, Katsuyuki and Hotta, Katsuyuki},
title = {Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
doi = {10.1007/s00432-024-05618-4}
}
EUVIMED